## 16TH MEETING | ATLANTA LUNG CANCER SYMPOSIUM 2022



Saturday, October 29, 2022, 7:55 AM-4:00 PM LOEWS ATLANTA HOTEL 1065 PEACHTREE STREET NE | ATLANTA, GA

## AGENDA

Pre-symposium Program Sponsored by Jazz Pharmaceuticals7:00-7:30 am <i>Title</i> : Following the ES-SCLC Patient Journey One Conversation at a Time Speaker: Tarek Mekhail, MD		
7:55-8:00 am	Welcome and Introduction	Suresh Ramalingam Kristin Higgins
	unotherapy (Management of Patients Without Driv na Leal and Paul Gill	ver Mutations)
8:00-8:20 am	Optimal Front-Line Treatment Approaches in NSCLC	Julie Brahmer
8:20-8:40 am	Managing IO Resistant NSCLC	Ticiana Leal
8:40-9:00 am	Immunotherapy in Small Cell Lung Cancer	Taofeek Owonikoko
9:00-9:30 am	Panel Discussion	
9:30-9:45 am	Break	
Plenary 2: Early Co-Chairs: Allan	-Stage NSCLC Pickens and Jeffrey Bradley	
9:45 -10:05 am	Neoadjuvant Therapies in Early-Stage NSCLC	Roy Herbst
10:05-10:25 am	Surgical Considerations in the Era of Improved Adjuvant and Neoadjuvant Therapies	Allan Pickens
10:25-10:45 am	How to Choose – Neoadjuvant vs Adjuvant in Resectable NSCLC	Paul Bunn
10:45-11:05 am	Unresectable Stage III NSCLC: Adding to the PACIFIC Regimen	Jhanelle Gray
11:05-11:25 am	Proton Therapy in Lung Cancer	Jeffrey Bradley
11:25-12:00 pm	Panel Discussion	
12:00-12:50 pm	Lunch	
	eted Therapy for NSCLC fer Carlisle and Kristin Higgins	
12:50-1:10 pm	Overcoming Acquired Resistance in EGFR-mutated NSCLC	Suresh Ramalingam
1:10-1:30 pm	Liquid Biopsy to Guide Treatment Decisions	Charu Aggarwal
1:30-1:50 pm	KRAS and EGFR Insertion 20 Mutated NSCLC	John Heymach
1:50-2:10 pm	Radiation Approaches for Oligometastatic and Oligoprogressive Disease in NSCLC with Driver Mutations	Kristin Higgins
2:10-2:30 pm	ALK/HER2/BRAF/RET/MET Mutated NSCLC	Jennifer Carlisle
2:30-2:50 pm	Panel Discussion	
	ical Management of Lung Cancer A Abdel Karim and Ioana Bonta	
2:50-3:10 pm	Optimizing Biomarker Testing Across the Lung Cancer Population	Nagla Abdel Karim
3:10-3:30 pm	Managing Brain Metastases	Kristin Higgins
3:30-3:50 pm	Challenging Cases	Linwood Millett (Emory Fellow)
3:50-4:00 pm	Closing Remarks	

## **CONFIRMED FACULTY:**

Kristin Higgins, MD (Co-Chair) Winship Cancer Institute of Emory University Atlanta, GA

Suresh Ramalingam, MD, FASCO (Co-Chair) Winship Cancer Institute of Emory University Atlanta, GA

Nagla Abdel Karim, MD, PhD Inova Cancer Institute, University of Virginia Fair Church, VA

**Charu Aggarwal, MD, MPH** University of Pennsylvania Philadelphia, PA

Jeffrey Bradley, MD, FASTRO Winship Cancer Institute of Emory University Atlanta, GA

Julie Brahmer, MD Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Baltimore, MD

Paul Bunn, MD University of Colorado Cancer Center Denver, CO

Jennifer Carlisle, MD Winship Cancer Institute of Emory University Atlanta, GA

Jhanelle Gray, MD Moffitt Cancer Center Tampa, FL

**Roy Herbst, MD, PhD** Yale School of Medicine New Haven, CT

John Heymach, MD, PhD The University of Texas MD Anderson Cancer Center Houston, TX

Ticiana Leal, MD Winship Cancer Institute of Emory University Atlanta, GA

**Linwood Millett, MD** Winship Cancer Institute of Emory University Atlanta, GA

Taofeek Owonikoko, MD, PhD, MSCR UPMC Hillman Cancer Center University of Pittsburgh Medical Center Pittsburgh, PA

Allan Pickens, MD Winship Cancer Institute of Emory University Atlanta, GA

## **STEERING COMMITTEE:**

**Michael Andrews, MD** Northwest Georgia Oncology Centers Atlanta, GA

**Ioana Bonta, MD** Georgia Cancer Specialists Atlanta, GA

**Paul Gill, MD** Atlanta Cancer Care Atlanta, GA

William Jonas, MD Piedmont Cancer Institute Atlanta, GA

Mohan Krishnamachary, MD Suburban Hematology-Oncology Consultants & Center for Cancer Care of Gwinnett Medical Center Atlanta, GA